{"id":54313,"date":"2026-04-23T13:04:19","date_gmt":"2026-04-23T13:04:19","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/54313\/"},"modified":"2026-04-23T13:04:19","modified_gmt":"2026-04-23T13:04:19","slug":"roche-expects-blockbuster-cancer-pill-launch-by-year-end","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/54313\/","title":{"rendered":"Roche Expects Blockbuster Cancer Pill Launch by Year End"},"content":{"rendered":"<p class=\"ArticleBodyText_articleBodyContent__17wqE typography_articleBody___5jDr\" data-component=\"paragraph\"><a href=\"https:\/\/www.bloomberg.com\/quote\/ROP:SW\" target=\"_blank\" rel=\"noopener nofollow\" class=\"media-ui-Link_link-tVkXhPLPofs-\" data-component=\"link\">Roche Holding AG<\/a> expects to launch the breast cancer pill that may become one of its biggest sellers by the end of the year, sparking optimism about its prospects. <\/p>\n<p class=\"ArticleBodyText_articleBodyContent__17wqE typography_articleBody___5jDr\" data-component=\"paragraph\">The medicine, called giredestrant, will likely win regulatory approval in the US in the last months of the year, Chief Executive Officer Thomas Schinecker said in a Bloomberg television interview. <\/p>\n","protected":false},"excerpt":{"rendered":"Roche Holding AG expects to launch the breast cancer pill that may become one of its biggest sellers&hellip;\n","protected":false},"author":2,"featured_media":54314,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[124],"tags":[2112,7437,4922,4397,10622,231,13223,3310,134,473,2559,5074,2561],"class_list":["post-54313","post","type-post","status-publish","format-standard","has-post-thumbnail","category-roche","tag-cancer","tag-chief-executive-officer","tag-currency","tag-drugs","tag-industries","tag-markets","tag-novartis-ag-reg","tag-regulation","tag-roche","tag-roche-holding-ag","tag-swiss-franc-spot","tag-thomas-schinecker","tag-us-dollar-spot"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116454166689503193","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/54313","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=54313"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/54313\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/54314"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=54313"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=54313"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=54313"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}